uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer
Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro, Sweden.
Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health. (Reproduktiv hälsa/Sundström Poromaa)
Show others and affiliations
2011 (English)In: American Journal of Obstetrics and Gynecology, ISSN 0002-9378, E-ISSN 1097-6868, Vol. 204, no 1, 26.e1-7 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To investigate the prevalence of urogenital symptoms and vaginal atrophy in postmenopausal breast cancer patients on adjuvant endocrine therapy. STUDY DESIGN: A population-based, cross-sectional study on postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched control subjects. Vaginal atrophy was assessed by gynecologic examination and atrophy-related symptoms by validated questionnaires. RESULTS: In all, 57.6% of aromatase inhibitor-treated and 32.4% of tamoxifen-treated breast cancer patients rated at least 1 vaginal atrophy symptom as moderate/severe, which was significantly more common than in control subjects (P < .01). Aromatase inhibitor-treated patients more often had moderate or severe vaginal atrophy (P < .05), a more atrophic cytohormonal evaluation, and significantly higher vaginal pH (P < .05) than all control subjects, irrespective of hormonal use. CONCLUSION: Our findings indicate that the frequency of vaginal atrophy symptoms, particularly in aromatase inhibitor-treated women, might have been underestimated in previous clinical trials.

Place, publisher, year, edition, pages
2011. Vol. 204, no 1, 26.e1-7 p.
Keyword [en]
aromatase inhibitors, breast cancer, tamoxifen, urogenital symptoms, vaginal atrophy
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-140073DOI: 10.1016/j.ajog.2010.08.035ISI: 000285622500011PubMedID: 20950790OAI: oai:DiVA.org:uu-140073DiVA: diva2:382869
Available from: 2011-01-03 Created: 2011-01-03 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Stavreus-Evers, AnneliKask, KristiinaKallak, TheodoraSundström-Poromaa, Inger

Search in DiVA

By author/editor
Stavreus-Evers, AnneliKask, KristiinaKallak, TheodoraSundström-Poromaa, Inger
By organisation
Department of Women's and Children's HealthDepartment of Oncology, Radiology and Clinical Immunology
In the same journal
American Journal of Obstetrics and Gynecology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 498 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf